Journal
CELL
Volume 142, Issue 4, Pages 511-512Publisher
CELL PRESS
DOI: 10.1016/j.cell.2010.08.004
Keywords
-
Categories
Ask authors/readers for more resources
Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available